Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.:Real-world evidence from Germany by März, Winfried et al.
 
 
Utilization of lipid-modifying therapy and low-
density lipoprotein cholesterol goal attainment in
patients at high and very-high cardiovascular risk:
Real-world evidence from Germany.
März, Winfried; Dippel, Franz-Werner; Theobald, Karlheinz; Gorcyca, Katherine; Iorga,
Serban R; Ansell, David
DOI:
10.1016/j.atherosclerosis.2017.11.020
License:
Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
März, W, Dippel, F-W, Theobald, K, Gorcyca, K, Iorga, SR & Ansell, D 2017, 'Utilization of lipid-modifying
therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular
risk: Real-world evidence from Germany. Real-world evidence from Germany', Atherosclerosis, vol. 268,
29197254. https://doi.org/10.1016/j.atherosclerosis.2017.11.020
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
First published in Atherosclerosis 2017
https://doi.org/10.1016/j.atherosclerosis.2017.11.020
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
lable at ScienceDirect
Atherosclerosis 268 (2018) 99e107Contents lists avaiAtherosclerosis
journal homepage: www.elsevier .com/locate/atherosclerosisUtilization of lipid-modifying therapy and low-density lipoprotein
cholesterol goal attainment in patients at high and very-high
cardiovascular risk: Real-world evidence from Germany
Winfried M€arz a, b, c, *, Franz-Werner Dippel d, Karlheinz Theobald e, Katherine Gorcyca f,
S¸erban R. Iorga g, David Ansell h
a Synlab Academy, Mannheim, Germany
b Medical Clinic V (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, University of Heidelberg,
Heidelberg, Germany
c Clinical Institute of Medical and Chemical Laboratory Diagnostics Medical, University of Graz, Graz, Austria
d Sanoﬁ-Aventis Deutschland GmbH, Berlin, Germany
e Sanoﬁ-Aventis Deutschland GmbH, Frankfurt, Germany
f Sanoﬁ US, Bridgewater, NJ, USA
g Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
h IMS Health, London, UKa r t i c l e i n f o
Article history:
Received 20 July 2017
Received in revised form
5 October 2017
Accepted 16 November 2017
Available online 20 November 2017
Keywords:
Cardiovascular diseases
Diabetes mellitus
LDL-C
Lipid-lowering therapy
LDL-C goal attainment
Real-world evidence
Germany* Corresponding author. SYNLAB Academy, P5, 7, 68
E-mail address: Winfried.Maerz@synlab.com (W. M
https://doi.org/10.1016/j.atherosclerosis.2017.11.020
0021-9150/© 2017 The Authors. Published by Elsevier
nd/4.0/).a b s t r a c t
Background and aims: Elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for
cardiovascular (CV) events. European guidelines recommend reducing LDL-C as the primary lipid target
to reduce CV risk, using lifestyle modiﬁcations and lipid-lowering therapy (LLT). Many European patients
do not achieve guideline-recommended LDL-C levels. The present database analysis aimed to assess LLT
treatment patterns and LDL-C threshold attainment in Germany in a large, real-world cohort of patients.
Methods: Patients from the Cegedim Longitudinal Practice Database in Germany who met selection
criteria were included: (a) LDL-C measurement in 2013; (b) 20 years of age; (c) high or very-high CV
risk conditions: recent acute coronary syndrome (ACS), other coronary heart disease (CHD), ischemic
stroke, peripheral arterial disease (PAD) (atherosclerotic cardiovascular disease [ASCVD]) or diabetes
mellitus (DM) (non-ASCVD). LDL-C threshold attainment was assessed based on LDL-C targets from 2011
European guidelines.
Results: 42,767 patients met the inclusion criteria; 35% received current statin treatment, and 30%
achieved guideline-recommended LDL-C targets. Attainment of LDL-C goals among ASCVD hierarchical
categories was 46.7% for recent ACS, 35.8% for ischemic stroke, 34.9% for other CHD, and 26.9% for PAD.
Among patients in the non-ASCVD group with DM, 23.6% achieved LDL-C goals. Similar results were
observed when patients were grouped by prevalence (patients assigned to every risk group for which
they qualiﬁed).
Conclusions: In this high/very-high CV risk population in Germany, statin utilization was low; suggesting
that LLTs are not prescribed as per European guidelines. These results highlight the need to increase LLT
use among high-risk patients.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite substantial decreases in cardiovascular (CV) disease
(CVD) death rates since 2003, CVD remains the main cause of161 Mannheim, Germany.
€arz).
Ireland Ltd. This is an open accessdeath in Europe, accounting for 31.5% of overall deaths [1]. In
Germany, CVD accounts for approximately 40% of deaths [2], or
148,538 deaths per year [3]. In 2014, the age-standardized death
rates for coronary heart disease (CHD) in Germany were 204.1
per 100,000 for men and 111.2 per 100,000 for women.
Decreasing low-density lipoprotein cholesterol (LDL-C) with
statins has been shown to reduce all-cause and CV mortalityarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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without ASCVD, including those with diabetes mellitus (DM)
[4e9]. A meta-analysis conducted by the Cholesterol Treatment
Trialists' (CTT) Collaboration demonstrated that for each 1 mmol/
L (38.7 mg/dL) reduction in LDL-C, a 22% relative reduction in
major CV events over a wide range of starting LDL-C levels was
achieved [6,7].
Despite the safety and tolerability of statins being well estab-
lished [6], appropriate statin use and LDL-C reduction may remain
suboptimal within clinical practice in Europe. A study in the
Netherlands found that lipid-lowering therapy (LLT) was used in
67% of patients at high CV risk, and overall, 55% of patients ach-
ieved an LDL-C goal <2.6 mmol/L (<100 mg/dL) [10]. Similarly,
among >180,000 high CV risk patients in the UK in 2014, 79% and
62% of ASCVD and non-ASCVD received statins, but only 31% and
26%, respectively, reached the LDL-C goal of <1.8 mmol/L (70 mg/
dL) [11]. In Germany, the proportions of patients with CVD
achieving risk-based LDL-C goals with statins has ranged from 14%
to 27% [12,13], and the proportion of German patients with CHD
receiving lipid-lowering therapy has been reported to be less than
35% [14].
In Germany, lipid treatment targets are aligned with the Eu-
ropean guidelines (European Atherosclerosis Society [EAS] and
European Society of Cardiology [ESC]) [15e18], whereby LDL-C
targets are based on the patient's CV risk. When data extraction
for the present study was conducted, the 2011 EAS/ESC guide-
lines were in place, which recommended LDL-C as the primary
lipid target to reduce CV risk [15]. When the guidelines were
updated in 2016, the strategy to reduce CV risk remained un-
changed [4,18]. To reduce LDL-C levels, a combination of lifestyle
modiﬁcations and LLT, including statins and non-statin therapies,
was advised within the 2011 EAS/ESC guidelines; however, sta-
tins were recommended as ﬁrst-line pharmacological treatment
of hypercholesterolemia [15]. The 2011 guidelines recommended
that patients with very-high CV risk (deﬁned as having CVD,
including previous myocardial infarction [MI], acute coronary
syndrome [ACS], coronary vascularization, coronary artery bypass
surgery and other arterial revascularization procedures, stroke
and peripheral artery disease [PAD]; type 1 or 2 DM with target
organ damage; severe chronic kidney disease [CKD]; or a calcu-
lated SCORE [Systemic Coronary Risk Estimation] 10% for 10-
year risk of fatal CVD) should achieve an LDL-C treatment goal
of <1.8 mmol/L (<70 mg/dL) and/or a 50% reduction from
baseline LDL-C. For patients designated to have high CV risk
(deﬁned as having markedly elevated single risk factors,
including familial dyslipidemias and severe hypertension; type I
or II DM, but without CV risk factors or target organ damage;
moderate CKD; or a calculated SCORE of 5% and <10% for 10-
year risk of fatal CVD), an LDL-C treatment goal of <2.6 mmol/L
(<100 mg/dL) was recommended [15].
The present database analysis assessed LLT treatment patterns
and LDL-C goal attainment relative to the EAS/ESC 2011 guide-
lines within a general practice setting in Germany in 2013. In a
large cohort of patients with established CVD and/or DM, we
assessed real-world LLT usage overall, and among patients with
ASCVD stratiﬁed by CV conditions (recent ACS, CHD, ischemic
stroke, and PAD), and non-ASCVD patients with DM. This study
provides critical updates to extend literature documenting that in
Germany, as well as more broadly, many patients do not achieve
the guideline-recommended LDL-C goals, even with long-term
LLT use. We contribute to this literature by providing estimates
of LLT usage and lipid goal attainment in Germany.2. Materials and methods
2.1. Database and cohort selection
A retrospective, observational, cross-sectional database analysis
of German patients at high or very-high CV risk was conducted
using data from the Cegedim Longitudinal Patient Database (LPD).
The database consisted of anonymized electronic medical records
(EMR) of 600,813 patients in Germany from ofﬁce-based practices
of approximately 500 German general practitioners (GPs), from
January 1, 2011 through December 31, 2013. The general practice
database is a large primary care database of GPs, consisting of
anonymized patient-level medical, prescription, socio-
demographic and laboratory results data and hospitalizations de-
tails. The study was conducted in accordance with applicable laws
and regulations in Germany, and guidelines for the performance
and evaluation of secondary data were considered [19]. Since the
study was a retrospective analysis, there was no requirement to
obtain speciﬁc Ethics Committee approval.
The following inclusion criteria were used: (a) presence of 1
lipid proﬁle in 2013 (the last LDL-C measurement in 2013 was
considered the index date); (b) 20 years of age as of the index
date; and (c) evidence of at least one high or very-high CV risk
condition at baseline, for which statins would be recommended as
per the EAS/ESC 2011 guidelines. At least 2 years of continuous
representation in the database prior to the index date (deﬁned as
the baseline period) were required to examine prior statin use.
2.2. Determination of ASCVD and non-ASCVD categories
Using the EAS/ESC 2011 guidelines as guidance, ﬁve high/very-
high CV risk mutually exclusive groups were deﬁned in the base-
line period, in the following decreasing order of relative impor-
tance: (a) recent ACS (MI or unstable angina requiring
hospitalization within the 12 months before the index date); (b)
other CHD (history of MI or unstable angina >12 months prior to
the index date and within the baseline period, stable angina, cor-
onary revascularization, or other chronic ischemic heart disease); c)
ischemic stroke (a history of ischemic stroke); (d) PAD (peripheral
vascular disease by non-coronary atherosclerotic disease, abdom-
inal aortic aneurysm), and carotid artery stenosis; and (e) DM (type
I and type II DM). High/very-high CV risk groupswere identiﬁed per
the International Classiﬁcation of Diseases, Tenth Revision (ICD-10)
diagnosis or procedure codes (Supplementary Table 1).
Patients were also categorized by overlapping prevalent condi-
tions, in which each patient was placed in every disease proﬁle for
which they qualiﬁed. For example, a patient with evidence of both
ischemic stroke and a prior PAD diagnosis would be categorized
into the ischemic stroke and PAD groups. Patients with recent ACS,
other CHD, ischemic stroke, and PADwere collectively referred to as
‘ASCVD’, while patients with DM without ASCVD were referred to
as non-ASCVD, and are presented separately. Per EAS/ESC deﬁni-
tions, ASCVD patients were all considered very-high risk, while DM
patients could have been high or very-high risk, depending on the
presence of additional risk factors.
2.3. Determination of LLT treatment
Current LLT treatment was assumed if, for a recorded prescrip-
tion of any days' supply, there was evidence of medication coverage
on or within 30 days before the index date. These patients were
designated as “currently treated” with LLT (Supplementary Fig. 1).
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the index date but not “currently treated” were considered to have
a history of LLT treatment. Patients with no evidence of a pre-
scription for LLT on the index date or during the 2 years before the
index date were considered to have no evidence of LLT treatment.
LLTs included in the any LLT category were: statins, ezetimibe,
ﬁbrates (gemﬁbrozil, fenoﬁbrate, fenoﬁbric acid, ciproﬁbrate and
bezaﬁbrate), bile acid sequestrants (cholestyramine, colesevelam
and colestipol) and niacin (nicotinic acid1). The any LLT group was
further divided into statin or non-statin LLT.
Statin use was grouped per a) overall statin therapy, b) high-
intensity statin therapy and c) low-to-moderate intensity statin
therapy, all either alone or in combination with other non-statin
LLT. High- and low-to-moderate intensity was deﬁned in accor-
dance with US American College of Cardiology (ACC)/American
Heart Association (AHA) guidelines, as EAS/ESC guidelines do not
deﬁne intensity [5]). High-intensity statin therapy included ator-
vastatin 40 and 80 mg, rosuvastatin 20 and 40 mg and simvastatin
80 mg daily. Low-to-moderate intensity statin therapy included all
other statin types and doses.2.4. Achievement of LDL-C thresholds on the index date
For ASCVD patients, we assessed the LDL-C threshold achieve-
ment as deﬁned in the EAS/ESC guidelines as per the target for
very-high CV risk (<1.8 mmol/L [<70 mg/dL]). We also assessed
achievement of the threshold for high-risk (1.8 to <2.6 mmol/L [70
to<100mg/dL]) to determinewhether ASCVD patients who did not
reach their risk-based threshold could achieve this less stringent
target. As DM patients without ASCVD could be considered high or
very-high risk, depending on the presence of additional risk factors,
we assessed the proportions of DM patients without ASCVD who
reached both thresholds.
The current LLT and LDL-C values were assessed concurrently
(i.e., overlapping with or on the index date), to ensure that lipid
levels best reﬂected the impact of the current treatment regimen.2.5. Statistical analysis
All statistical analyses conducted for this study were descriptive
in nature. Demographic, clinical, and medication characteristics,
LLT utilization, and achieved lipid levels were summarized using
proportions or mean ± standard deviation (SD) per the character of
the variable (categorical or continuous). All analyses were con-
ducted with SAS® software V.9.4.3. Results
3.1. Patient demographics and clinical characteristics
From 600,813 patients living in Germany, whowere represented
in the database, 42,767 patients met the inclusion criteria and were
included in the sample (Supplementary Fig. 2). The mean age was
69.3 years (SD 11.9), and 52.9% were male (Table 1). Sixty percent of
patients had evidence of ASCVD, and per hierarchical disease
categorization, 1% had recent ACS, 48% had other CHD, 3% had a
history of ischemic stroke, and 8% had PAD. Forty percent of pa-
tients had DM without ASCVD. Baseline characteristics of the
ASCVD and non-ASCVD groups by prevalent categorization are
presented in Supplementary Table 2.1 Withdrawn from German market in January 2013.3.2. Lipid-lowering therapy use
3.2.1. Overall cohort
In total, 36.3% of patients in the cohort were deﬁned as currently
treated with LLT; 35.0% received statins (2.8% and 32.2% of patients
received high- and low-to-moderate intensity statin, respectively),
and 1.3% of patients received non-statin LLT only. Of the patients
treated with low-to-moderate intensity statin therapy, 1.4% had
evidence of a previous high-intensity statin prescription. A large
proportion of patients (63.7%) did not have current evidence of any
LLT, 50.2% had no written prescription for an LLT during the 2 years
prior to the index date, and 13.5% had a previous (but no current)
LLT prescription (Fig. 1).
3.2.2. ASCVD population
Among ASCVD patients, 44.9% received any LLT; and 43.6% of
patients received prescriptions for statins on the index date. Fig. 2
shows the statin use at the index date by hierarchical risk cate-
gories. The proportion of patients with a current prescription for
statins was highest among recent ACS patients at 58.7%, followed
by ischemic stroke patients (46.0%) and other CHD patients (44.5%).
The proportion of patients with a current prescription for statins
was lowest among patients with PAD (34.8% [Fig. 2]). The stratiﬁ-
cation of previous statin use by intensity level among patients with
no current statin LLT can be seen in Fig. 2; previous use of statins
was lowest among PAD patients (11.9%).
3.2.3. DM (non-ASCVD population)
By hierarchical risk categories, among non-ASCVD patients with
DM, 23.3% received any LLT. The proportion of patients with a
current prescription for statins was 21.9%; 20.6% of which received
low-to-moderate intensity statins while 1.3% received high-
intensity statins (Fig. 2). The proportion of patients with no statin
LLT was 78.1% (Fig. 2).
3.3. EAS/ESC-recommended LDL-C goal attainment
In the overall cohort at the index date, the mean (SD) LDL-C was
3.2 (1.0) mmol/L (122.5 mg/dL), and the overall proportion of pa-
tients attaining LDL-C thresholds of <1.8 mmol/L (<70 mg/dL) and
1.8 to <2.6 mmol/L (70 to <100 mg/dL) on the index date was 7.2%
and 22.8%, respectively (i.e. 30% < 2.6 mmol/L [<100 mg/dL]). The
proportions of patients currently with any LLT therapy achieving
LDL-C thresholds were 13.5% and 36.8%, respectively.
A higher proportion of patients with LDL-C <1.8 mmol/L
(<70 mg/dL) (64.4%) or 1.8 to <2.6 mmol/L (70 to <100 mg/dL)
(56.6%) had prescriptions for statin therapy comparedwith patients
with LDL-C>2.6mmol/L (>100mg/dL) (Fig. 3). The inversewas true
for the proportions of patients receiving no current LLT.
3.3.1. ASCVD population
In the ASCVD population, the mean (SD) LDL-C was
3.0 (1.0) mmol/L (117.8 mg/dL) with 8.5% of patients achieving
LDL-C <1.8 mmol/L (<70 mg/dL) and 25.6% of patients achieving
LDL-C 1.8 to <2.6 mmol/L (70 to <100 mg/dL).
Among the ASCVD hierarchical categories, the highest levels of
LDL-C threshold achievement (<1.8 mmol/L [<70 mg/dL] and 1.8 to
<2.6 mmol/L [70 to <100 mg/dL]) were observed in patients with
recent ACS (11.5% and 35.2%), followed by ischemic stroke (9.8% and
26.0%), other CHD (8.8% and 26.1%), and PAD (6.0% and 20.9%)
(Fig. 4A).
When disease state was categorized by prevalence, the highest
levels of achievement of both thresholds were observed in patients
with recent ACS (11.5% and 35.2%), followed by ischemic stroke
(10.8% and 27.7%), PAD (9.1% and 26.4%), and other CHD (8.8% and
Table 1
Baseline characteristics and co-morbidities of selected general practice patients in Germany in 2013, classiﬁed by high and very-high CV risk-based conditions (in decreasing
order).
Overall cohort
(n ¼ 42,767)
Decreasing-order hierarchy of very-high CV risk conditions
ASCVD Non-ASCVD
Recent ACS
(n ¼ 566)
CHD
(n ¼ 20,665)
Ischemic stroke
(n ¼ 1275)
PAD
(n ¼ 3352)
Diabetes
(n ¼ 16,909)
Age (continuous), mean (SD) 69.3 (11.9) 69.4 (11.9) 71.8 (10.9) 72.0 (11.2) 70.6 (10.7) 65.9 (12.5)
Male, n (%) 22,607 (52.9) 377 (66.6) 11,883 (57.5) 693 (54.4) 1712 (51.1) 7942 (47.0)
Recent ACS, n (%) 566 (1.3) 566 (100.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Chronic CAD, n (%) 20,665 (48.3) 0 (0.0) 20,665 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Ischemic stroke, n (%) 2190 (5.1) 31 (5.5) 884 (4.3) 1275 (100.0) 0 (0.0) 0 (0.0)
PAD, n (%) 7073 (16.5) 103 (18.2) 3389 (16.4) 229 (18.0) 3352 (100.0) 0 (0.0)
DM, n (%) 28,558 (66.8) 224 (39.6) 9384 (45.4) 573 (44.9) 1468 (43.8) 16,909 (100.0)
Comorbidities
Hypertension, n (%) 25,014 (58.5) 320 (56.5) 12,812 (62.0) 748 (58.7) 1873 (55.9) 9261 (54.8)
History of CHF, n (%) 4895 (11.4) 92 (16.3) 3362 (16.3) 113 (8.9) 303 (9.0) 1025 (6.1)
Chronic stage kidney disease, n (%) 1582 (3.7) 45 (8.0) 983 (4.8) 51 (4.0) 132 (3.9) 371 (2.2)
Stage III 880 (2.1) 27 (4.8) 553 (2.7) 31 (2.4) 68 (2.0) 201 (1.2)
Stage IV-V (dialysis) 706 (1.7) 17 (3.0) 430 (2.1) 24 (1.9) 61 (1.8) 174 (1.0)
Dementia, n (%) 1283 (3.0) 14 (2.5) 733 (3.5) 79 (6.2) 101 (3.0) 356 (2.1)
COPD, n (%) 7707 (18.0) 107 (18.9) 4325 (20.9) 183 (14.4) 588 (17.5) 2504 (14.8)
Moderate/severe liver disease, n (%) 66 (0.2) 1 (0.2) 28 (0.1) 2 (0.2) 9 (0.3) 26 (0.2)
ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease CHD, coronary heart disease; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CV, cardiovascular; DM, diabetes mellitus; PAD, peripheral artery disease; SD, standard deviation.
Fig. 1. LLT treatment patterns in a general practice setting in Germany as of 2013.
Current treatment is assumed based on prescription information. *207 patients were currently treated with ezetimibe alone. LLT, lipid-lowering therapy.
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Among patients not on LLT, when the disease states were
deﬁned hierarchically, the highest levels of achievement of both
goals (<1.8 mmol/L [<70 mg/dL] and 1.8 to <2.6 mmol/L [70 to
<100 mg/dL]) were observed in patients with recent ACS (2.7% and
23.1%), followed by ischemic stroke (2.5% and 16.2%), and PAD (3.3%
and 14.4%), and were lowest among other CHD patients (3.3% and
13.8%) (Fig. 4C).3.3.2. DM (non-ASCVD population)
Among non-ASCVD patients with DM, the mean (SD) LDL-C was
3.3 (1.0) mmol/L (127.4 mg/dL).
When deﬁned hierarchically, the proportion of patients with
DM achieving target LDL-C thresholds (<1.8 mmol/L [<70 mg/dL]
and 1.8e2.6 mmol/L [70e100 mg/dL]) were 5.1% and 18.5%,respectively (Fig. 4A) (i.e. 23.6% < 2.6 mmol/L [<100 mg/dL]). When
deﬁned by prevalence, the proportion of patients with DM
achieving the target LDL-C thresholds were 7.6% and 22.4% (Fig. 4B).
The proportions of DM patients not on LLT achieving LDL-C
thresholds were 15.0% and 3.3% (Fig. 4C).4. Discussion
In this study, despite patients being at high or very-high risk of
CV events, only 35% received statins, and most statin-treated pa-
tients (32.2%) were receiving low-to-moderate intensity statin.
Additionally, LDL-C threshold attainment in the overall cohort of
German patients with established ASCVD and/or DMwas low, with
only 7.2% reaching <1.8 mmol/L (70 mg/dL) and 22.8% reaching 1.8
to <2.6 mmol/L (70 to <100 mg/dL).
Fig. 2. Statin use by hierarchical CV risk subgroups at index date.
ASCVD, atherosclerotic cardiovascular disease; ACS, acute coronary syndrome; CHD, coronary heart disease; DM, diabetes mellitus; PAD, peripheral artery disease.
Fig. 3. Utilization of LLT in the overall cohort by LDL-C category.
LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy.
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including in Germany, for reducing LDL-C levels, as well as pre-
venting CV events and ASCVD development. The 2011 EAS/ECS
guidelines, which were effective at the time of the current inves-
tigation, recommended that patients at high CV risk should receiveLLT to reach target LDL-C levels <2.6 mmol/L (<100 mg/dL),
whereas patients at very-high CV risk should receive LLT to reach
target LDL-C levels <1.8 mmol/L (<70 mg/dL) and/or 50% reduc-
tion from baseline LDL-C levels [15]. Contrary to the 2011 EAS/ESC
guidelines recommendations, a high percentage of German
Fig. 4. Achievement of LDL-C thresholds in the overall cohort.
(A) By hierarchical CV risk group on the index date.* (B) By prevalent classiﬁcation of CV risk categories* on index date. (C) Achievement of LDL-C goals among patients not on lipid-
lowering therapy by hierarchical CV risk group on index date. *Regardless of therapy received. ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; CHD,
coronary heart disease; CV, cardiovascular; DM, diabetes mellitus; LDL-C, low-density lipoprotein cholesterol; PAD, peripheral artery disease.
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W. M€arz et al. / Atherosclerosis 268 (2018) 99e107 105patients in the overall cohort were not currently receiving any LLT
(63.7%), despite being at high or very-high CV risk. Among patients
with ASCVD, 43.6% were currently prescribed statin treatment;
39.8% received low-to moderate intensity statins, and 3.8% received
high-intensity statins. Percentages were lower in the non-ASCVD
group, with 21.9% prescribed statin treatment, of which 20.6%
received low-to-moderate intensity statins, and 1.3% received high-
intensity statins. The results of our study suggest that many
German patients in need of LDL-C-lowering are not receiving statin
LLT, and that there is considerable discordance between clinical
practice in 2013 in Germany and the 2011 EAS/ESC guidelines that
were in effect at the time of this study [15]. It is well established
that a reduction in LDL-C levels among high and very-high risk
patients can signiﬁcantly reduce the risk of CV events [6]. There-
fore, closely implementing the guidelines represents best practice,
and would ultimately reduce the risk of CV events.
Despite the discordance with the 2011 EAS/ESC guidelines, our
results are similar to those observed in other studies [10,11,20]. An
analysis from the DYSIS study comparing LDL-C goal achievement
in patients enrolled in Germany versus patients in the UK found
that patients in Germany received high-intensity statins less often
than UK patients. Additionally, the daily dosages of statins used in
Germany were signiﬁcantly lower than in the UK, resulting in
signiﬁcantly fewer patients in Germany attaining the recom-
mended treatment goal of LDL-C <1.8 mmol/L (<70 mg/dL) or LDL-
C <2.6 mmol/L (<100 mg/dL) [21].
We have not investigated the reasons of the participating doc-
tors for their therapeutic decisions, but they are probably complex.
A recent paper provided possible explanations for the low use of
high dose atorvastatin and achievement of LDL-C targets in only a
minority of patients, including the physicians' desire to avoid po-
tential side effects which may be associated with higher doses
(although this does not seem to be as much a concern for UK cli-
nicians), and a lack of awareness of the applicable guidelines (EAS/
ESC) [22].
Another reason for the relatively low goal attainment among the
German population studied could be due to differences in the
healthcare system compared with other countries. For example, in
the UK, the Quality and Outcomes Framework is a system for the
performance management and payment of GPs, which was in place
at the time of this study. For CVD in particular, GPs were incen-
tivized with additional remuneration to ensure patients who have a
recorded QRISK2 (UK population derived CVD risk score like Fra-
mingham) score of20% in the preceding 12months are prescribed
statins [23,24]. In Germany, in contrast to the UK, physicians have a
restricted drug budget per patient, and are threatened penalty
payments if they exceed this budget. This may explain why statin
prescribing is lower than the UK, and fewer patients achieve LDL-C
target levels in Germany [21]. Given that more high CV risk patients
achieve target LDL-C levels in the UK through employing an alter-
native positive reimbursement, we suggest that German health
politicians investigate alternative or additional reimbursement
strategies rewarding preventive measures.
As mentioned previously, the EAS/ESC targets are deﬁned per
the total CV risk level of each patient. For patients at very-high CV
risk, the goal is an LDL-C <1.8 mmol/L (70 mg/dL), whereas for
patients at high CV risk, the goal is LDL-C <2.6 mmol/L (<100 mg/
dL). All ASCVD patients are classiﬁed as very-high risk. Among the
ASCVD population, when deﬁned hierarchically, the proportion
who achieved LDL-C <1.8 mmol/L (70 mg/dL) ranged from 6.0% to
11.5%. The highest levels of achievement of LDL-C thresholds were
observed among patients with recent ACS, while the lowest levels
of achievement were observed among patients with PAD. Findings
were similar when patients were deﬁned by prevalence.
Classiﬁcation of DM patients without ASCVD as high or very-high risk was not feasible in this study for several reasons. Firstly,
as DM patients with moderate or severe CKD are considered very-
high risk, it would be necessary to determine CKD severity; how-
ever, CKD has been shown to be poorly documented within the
German LPD. Although moderate and severe CKD is one of the EAS/
ESC very-high CV risk categories, it was not possible to obtain
estimated glomerular ﬁltration rate (eGFR) results in a manner
permitting rigorous CKD identiﬁcation. Within this study, CKD
stages 3e4e5 were captured from ICD codes as a comorbidity, and
3.7% of patients were observed to have CKD stage 3e4e5; however,
in a recent study among a similar population of patients, the
prevalence of CKD was estimated at almost 30% [25]. The lower
number of patients observed to have CKD stage 3e4e5 within this
study is likely to be underestimated due to missing coding of CKD
by GPs. Secondly, SCORE risk was not calculated for these patients.
Finally, it would be necessary to identify patients with severe hy-
pertension (another additional risk factor that leads to classiﬁcation
as very-high risk), but there is no agreed deﬁnition for severe hy-
pertension in DM patients. Therefore, our cohort of DM patients
without ASCVD likely included patients at both high and very-high
risk. The proportion of these who achieved target LDL-C thresholds
were even lower than for the ASCVD cohort, at 5.1% and 7.6% for
LDL-C <1.8 mmol/L (70mg/dL), and 18.5% and 22.4% for LDL-C 1.8 to
<2.6 mmol/L (70 to <100 mg/dL), when deﬁned hierarchically and
by prevalence, respectively. Increasing statin intensity may help
greater numbers of patients reach the goal. However, even so, it is
unlikely that an average LDL-C target of <1.8 mmol/L (<70 mg/dL),
or 1.8 to <2.6 mmol/L (70 to <100 mg/dL), as recommended by the
EAS/ESC guidelines, would be reached within this population with
statin therapy alone. This highlights that there may be a role for
alternative evidence-based therapies for further LDL-C lowering.
Although previous studies have looked at LLT utilization and
goal attainment in European patients, the present study aimed to
provide critical updates to extend the literature by providing recent
estimates of LLT use and lipid goal attainment in Germany. The
ﬁndings from this study are consistent with earlier studies on LLT
utilization and poor goal attainment in patients considered at high
risk of CV events [10,11,20]. A recent analysis of the international
DYSIS study showed that only 26.8% of patients attained their risk-
based target LDL-C level, and of the 76% of patients classiﬁed as
being at very-high risk, only 21.7% attained their LDL-C goal [26].
Furthermore, in the German DYSIS cohort (approximately 4000
patients), only 10.7% attained the high or very-high risk-based LDL-
C targets [12]. Similarly, a cross-sectional cohort study of Belgian
DYSIS patients receiving statins showed that, overall, 56.2% of pa-
tients did not achieve the LDL-C target, and among patients at very-
high risk almost three-quarters did not achieve LDL-C target [27].
The results of the present study are concerning, as it has been
demonstrated that the greater the LDL-C reduction, the greater the
CV risk reduction [6]; therefore, poor attainment of the LDL-C target
is likely to be associated with poor CVD outcomes. Data on target
attainment by CV risk group in European patients are limited, but in
a Japanese study, attainment was lowest for CHD (55%) and highest
for ischemic stroke, PAD and DM patients (80%). This contrasts with
our ﬁndings, where DM had the lowest percentage achieving LDL-C
treatment thresholds, which may reﬂect differences in clinical
practice in Germany versus Japan [28], and the higher rates of DM
in Germany.
4.1. Limitations
Some study limitations must be noted. As the analyses were
conducted retrospectively, it was not possible to identify the causes
of low LLT utilization and poor achievement of LDL-C targets in
Germany. However, the data do allow us to expand our knowledge
W. M€arz et al. / Atherosclerosis 268 (2018) 99e107106on how LLTs are currently being utilized within a German
population.
The cohort represents a German population within a general
practice setting, which may limit the generalizability of results, as
high or very-high CV risk patients being treated exclusively by a
specialist (e.g., cardiologist, endocrinologist) would not be
captured. Additionally, LDL-C measurements were not prospec-
tively speciﬁed, which may introduce biases as the populationwith
LDL-C measurement may differ compared with the overall popu-
lation. The characterization of medical conditions was limited to
EMRs. No information on additional risk factors such as smoking,
diet and exercise habits were available. It cannot be guaranteed that
the medication prescriptions given to patients were dispensed by
pharmacists, or that the medicines dispensed were taken as pre-
scribed. Results were reported as unadjusted descriptive sum-
maries and cannot account for the inﬂuences of baseline
characteristics on statin utilization or lipid levels. For example,
importantly, adherence and its effects on LDL-C goal attainment for
patients with LLT were not assessed. Insights into the underlying
reasons for low or sub-optimal statin treatment are limited. Finally,
the study did not include an evaluation of statin monotherapy
versus statin plus other LLT (e.g., ezetimibe).4.2. Conclusions
Safe and effective LLTs with proven CV protective effects are
available in Germany. However, this study suggests that LLTs are not
being utilized in the manner advised by ESC and EAS guidelines.
This could be due to several factors, including patient preference,
statin intolerance and prescribing patterns. In a large proportion of
patients, this may contribute to suboptimal goal attainment and
avoidable morbidity andmortality; however, it is important to note
that other factors (e.g., treatment adherence), may also have a
signiﬁcant impact. These results highlight the need to ensure
compliance with guidelines, so that patients receive adequate
available LLT. Furthermore, for those patients who do not reach
LDL-C goal despite statin therapy, it may be necessary to consider
alternative therapeutic options to lower their CVD risk.Conﬂict of interest
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